Members Area Login

Go to the login page

Want to be a Member?

Click here
Contact us

IPEC Europe

Supporting the interests of pharmaceutical excipient developers, producers, distributors and users.

Meet the Board


Frithjof Holtz

IPEC Europe Chair


Mr. Frithjof Holtz is a biologist and has been working for more than 26 years with Merck KGaA, Darmstadt, Germany, having a long year experience in quality assurance and regulatory affairs. Besides experience in chemical manufacturing (excipients/APIs) he has also working experience in quality assurance for drug products (sterile/non-sterile).


Furthermore he is now working for more than 12 years in Regulatory Affairs (CMC) for pharmaceutical starting materials. Currently he is responsible for the coordination of the advocacy & surveillance activities of Merck Life Science.




Frank Milek

IPEC Europe Vice-Chair




Dr. Frank Milek is an industrial pharmacist and has been working in pharmaceutical excipients industry for more than 15 years, specialised in the field of supply chain and distribution. He is registered QP according to EU regulation and responsible at Aug. Hedinger GmbH & Co. KG for Quality, Regulatory Affairs and GMP.


Frank is currently the Vice-Chair of IPEC Federation, as well as Chair of the IPEC Europe GDP Committee and an active member of the EXCiPACT association. In parallel, he also chairs the GTDP Committee in FECC (European Association of Chemical Distributors).




Dominik Odenbach       

IPEC Europe Treasurer


Dr. Dominik Odenbach is a biologist working for more than 10 years in the pharmaceutical industry in various positions in production and mainly regulatory affairs for companies like Abbott and BASF.


In his current role as Director for Global Regulatory & External Affairs, he is responsible for all regulatory affairs activities in Pharma Solutions business of BASF.


Karine Roth

IPEC Europe Secretary


Karine Roth is a Pharmacist and has more than 20 years of experience within Pharmaceutical Industry.


She is currently working with Novartis as Global  Head Quality Cell & Gene Therapy (C&GT) Network; her role includes Quality oversight for development, commercialization and manufacturing of  C&GT therapies, for all Novartis assets. Previously she used to lead different quality organization looking at  Technical development of Biologics, QA Oversight of suppliers and parenteral contract manufacturers.


Prior Novartis, she has worked for Eli Lilly in several management position in Regulatory, Quality Assurance and Operational Excellence.


Marie Lesenne


Marie Lesenne is an engineer who has been working for Roquette since mid-2001 in several position such as Site QA Manager, responsible of several products release or Pharmaceuticals and Cosmetics Quality Manager, responsible of product complaint investigation, documentation review and on-site customer audits.

She is now the Head of Global Customer QA in charge of a team of approx. 20 people taking care of quality commitments and documentation (specifications, questionnaires, quality statements and agreements...) and guaranteeing the quality robustness and performance of Roquette at a global level to ensure customers satisfaction.





Amina Faham


Amina earned a Ph.D. degree in Pharmaceutical Sciences from School of Pharmacy, University de la Mediterranée France. Amina has over 15 years of pharma industry experience and strong knowledge on regulatory affairs support of submissions and on-going regulatory compliance for product development process.


She joined DOW Europe in Switzerland in 2011, as a pharmaceutical application specialist to drive and support the pharma business growth in Europe Middle East and Africa, and then moved into a global leadership role in Pharma R&D organization. One of Amina’s main responsibilities is to use her pharmaceutical technical expertise to closely connect to the innovation needs of the pharmaceutical industry.


Liz Meehan


Liz Meehan is a material scientist with a PhD from City University, London and more than 30 years experience in material characterisation.


She has worked in the pharmaceutical industry for 10 years, in the Pharmaceutical Development department of AstraZeneca, specialising in the field of excipient characterisation, relating excipient properties to functionality in dosage form design. More generally her activities include excipient risk assessment/mitigation for the development of robust pharmaceutical formulations.




Mahmud Yunis


Dr. Mahmud Yunis has been working for 13 years at BIOGRUND in several positions.


In his current function as Technical Director, he is responsible for preparing and implementing global strategic regulatory plan for BIOGRUND products and the strategic development of the Quality, Production and R&D department. He has a PhD degree in Analytical Chemistry from University of Muenster, Germany.  Before joining BIOGRUND he worked for a consulting company on the area of GxP procedures and processes for five years.


Newsletter Subscription

Sign up for our subscriber newsletter!

I have read and agree to the IPEC Europe Privacy Policy